ERBB2 and breast cancer: These findings not only provide a new insight of lapatinib-induced motility of TNBC cells, but also suggest that targeting IL-6 may be a potential strategy to reduce the recurrence and metastasis of breast cancer in combination with EGFR/HER2 TKIs.